Annexon Reports Rapid, Clinically Meaningful Responses in First GBS Patients Treated with Tanruprubart in FORWARD Study
ANNX has more than doubled off its 52-week low of $2.03.
Summary
Annexon announced positive early clinical data from the FORWARD study, showing rapid and clinically meaningful improvement in all ten GBS patients treated with tanruprubart. The results support a BLA submission targeted for Q4 2026 and could lead to the first approved targeted therapy for GBS.
Key Events · Product Development and Regulatory · ANNX
-
Positive Early FORWARD Data
All ten patients in the first U.S. and European cohort showed rapid, clinically meaningful improvement in muscle strength within four days of a single tanruprubart infusion. Four bedbound patients walked within eight days; one ventilated patient was extubated within four days.
-
Regulatory Path De-Risked
Data reinforce consistency with prior Phase 3 and real-world evidence, supporting a BLA submission targeted for Q4 2026. EMA review of the MAA is already underway.
-
Large Market Opportunity
GBS affects ~22,000 patients annually in the U.S. and Europe, with an estimated >$20 billion annual U.S. healthcare burden. No approved targeted therapies exist.
-
Next Milestones
Full FORWARD data to be presented at upcoming medical conferences; BLA submission targeted for Q4 2026.
Analysis · ANNX · Life Sciences
The first U.S. and European patient cohort from the FORWARD study showed rapid, clinically meaningful improvement in strength and reduced disability within days of a single infusion of tanruprubart. All ten patients improved, with four bedbound patients walking within eight days and one ventilated patient coming off the ventilator within four days. These early results reinforce the consistency of the treatment effect seen in prior Phase 3 and real-world evidence studies, strengthening the case for regulatory approval. With a BLA submission targeted for Q4 2026 and EMA review already underway, this data meaningfully de-risks the lead program and could position tanruprubart as the first approved targeted therapy for GBS, a market with an estimated >$20 billion annual U.S. healthcare burden.
At the time of this filing, ANNX was trading at $5.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $879.8M. The 52-week trading range was $2.03 to $7.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.